SCHEMBL21742932

SCHEMBL21742932

CON(C)C(=O)c1cc(C)nc(C2CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 4/20 0.41
MLYCD O95822 1/20 0.35
HCRTR1 O43613 3/20 0.34
HCRTR2 O43614 3/20 0.34
PDE10A Q9Y233 1/20 0.34
ACKR3 P25106 1/20 0.33
CLK1 P49759 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
CNR1 P21554 1/20 0.32
KCNH2 Q12809 1/20 0.32
AURKB Q96GD4 1/20 0.32
POLB P06746 1/20 0.32
MTOR P42345 1/20 0.32
TLR9 Q9NR96 2/20 0.32
TLR8 Q9NR97 2/20 0.32
TLR7 Q9NYK1 2/20 0.32
GPR119 Q8TDV5 3/20 0.31
PROKR1 Q8TCW9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361909 0.83 MLYCD (0.42) MLYCDCLK1DYRK1ADYRK1BPOLB
SCHEMBL2713615 0.77 MLYCD (0.39) MLYCDCLK1DYRK1ADYRK1BPOLB
SCHEMBL21743152 0.77 NPC1 (0.39) KDM5AACKR3POLBTLR9TLR8
SCHEMBL21326171 0.77 POLB (0.44) KDM5APOLBPROKR1
SCHEMBL3926252 0.76 GPBAR1 (0.45) MLYCDCLK1DYRK1ADYRK1BKCNH2
SCHEMBL18176056 0.75 POLB (0.39) KDM5AACKR3POLBPROKR1
SCHEMBL16706128 0.74 KDM5A (0.53) KDM5AACKR3POLB
SCHEMBL12093165 0.73 HCRTR1 (0.35) MLYCDHCRTR1HCRTR2CNR1KCNH2
SCHEMBL24664554 0.72 MLYCD (0.40) MLYCDHCRTR1HCRTR2CLK1DYRK1A
SCHEMBL1424936 0.71 KMO (0.44) KDM5AACKR3POLBPROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319321-B2 [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 US disclosed
US-20200055858-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055858-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS PDE2A, PDE12, PDE5A KDM5A 567/4885MLYCD 3242/4885HCRTR1 3978/4885
US-11319321-B2 [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors PDE2A, PDE12, PDE5A KDM5A 567/4885MLYCD 3242/4885HCRTR1 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.